Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Type (Autologous Stem Cells, Autologous Non-Stem cells), Application, End-User and Geography

Market Snapshot

autologous stem cell and non-stem cell based therapies
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 14.26 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • The Autologous Stem Cell and Non-Stem Cell-Based Therapies market is anticipated to grow with a CAGR of nearly 14.26%, during the forecast period. Certain factors that are driving the market growth include rising prevalence of targeted diseases, the introduction of novel autologous stem cell-based therapies in regenerative medicine and increasing of the geriatric population.
  • Stem cell technology is found to be a speedily developing technology which plays a major role in regenerative medicine, as it also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. Stem cells offer the possibility of replacing the cells and tissues to treat various conditions including spinal cord injury, arthritis, and Parkinson’s disease, among others.
  • The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world.
  • The advantage of autologous stem cell transplant is that one is getting one’s own cells back. This means there is no risk that the immune system of the individual will reject the transplant or that the transplanted cells will attack or reject the individual’s body.

Scope of the Report

An autologous stem cell therapy or stem cell transplant uses healthy blood stem cells from one’s own body to replace one’s diseased or damaged bone marrow, and as far as non-stem cell based therapy is concerned, autologous platelet-rich plasma (PRP) is a treatment which contains fibrin and high concentrations of growth factors with the potential to improve the healing of chronic wounds.

By Type
Autologous Stem Cells
Autologous Non-Stem cells
By Application
Neurodegenerative Disorders
Cardiovascular Disease
Orthopedic Diseases
By End-User
Ambulatory Surgical Centers
Research Facilities
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cancer Holds Significant Share in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

  • Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could stem this trend, and prevent as many as one-third of cancers, worldwide.
  • The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,210 estimated new cancer cases and 595,690 deaths due to cancer in 2016, in the United States.
  • The National Cancer Institute reports that more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world’s cancer deaths also occur in these regions. The International Agency for Research on Cancer (IARC) predicts that by 2030, the global burden is expected to rise to 21.7 million new cancer cases and 13 million cancer deaths, simply due to growth and aging of population, leaving aside factors, such as smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries.
  • According to WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer policy. This global and extensive threat of cancer remains a major market driver for new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.

North America Dominates the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

  • North America dominated the overall stem cell market with the United States contributing to the largest share in the market.
  • The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.
  • In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cell–based therapy in patients with chronic spinal cord injury.
  • Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.
Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2

Competitive Landscape

The global Autologous Stem Cell and Non-Stem Cell-Based Therapies market is competitive and consists of a few major players. The companies includes Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Regeneus Ltd, U.S. Stem Cell, Inc, among others, hold the substantial market share in the growth of overall market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Targeted Diseases

      2. 4.2.2 Introduction of Novel Autologous Stem Cell Based Therapies in Regenerative Medicine

      3. 4.2.3 Increasing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Autologous Cellular Therapies

      2. 4.3.2 Lack of Skilled Professionals

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Autologous Stem Cells

      2. 5.1.2 Autologous Non-Stem cells

    2. 5.2 By Application

      1. 5.2.1 Cancer

      2. 5.2.2 Neurodegenerative Disorders

      3. 5.2.3 Cardiovascular Disease

      4. 5.2.4 Orthopedic Diseases

      5. 5.2.5 Others

    3. 5.3 By End-User

      1. 5.3.1 Hospitals

      2. 5.3.2 Ambulatory Surgical Centers

      3. 5.3.3 Research Facilities

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Novartis International AG

      2. 6.1.2 BrainStorm Cell Limited.

      3. 6.1.3 Caladrius Biosciences Inc.

      4. 6.1.4 Cytori Therapeutics Inc.

      5. 6.1.5 Dendreon Pharmaceuticals LLC

      6. 6.1.6 Castle Creek Biosciences Inc.

      7. 6.1.7 Pharmicell Co. Ltd

      8. 6.1.8 Regeneus Ltd

      9. 6.1.9 U.S. Stem Cell, Inc.

      10. 6.1.10 Gilead Sciences Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Autologous Stem Cell and Non-Stem Cell Based Therapies Market market is studied from 2018 - 2026.

The Autologous Stem Cell and Non-Stem Cell Based Therapies Market is growing at a CAGR of 14.26% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

U.S. Stem Cell, Inc., BrainStorm Cell Limited., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Novartis AG are the major companies operating in Autologous Stem Cell and Non-Stem Cell Based Therapies Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!